Nisa Investment Advisors LLC Boosts Holdings in Boston Scientific Corporation $BSX

Nisa Investment Advisors LLC increased its position in Boston Scientific Corporation (NYSE:BSX) by 1.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 391,013 shares of the medical equipment provider’s stock after purchasing an additional 7,200 shares during the period. Nisa Investment Advisors LLC’s holdings in Boston Scientific were worth $38,175,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. G&S Capital LLC grew its holdings in shares of Boston Scientific by 2.4% during the third quarter. G&S Capital LLC now owns 25,992 shares of the medical equipment provider’s stock valued at $2,538,000 after buying an additional 611 shares during the last quarter. WD Rutherford LLC boosted its stake in Boston Scientific by 39.0% during the 3rd quarter. WD Rutherford LLC now owns 22,849 shares of the medical equipment provider’s stock valued at $2,231,000 after purchasing an additional 6,414 shares during the last quarter. Strategic Planning Group LLC purchased a new stake in Boston Scientific during the 3rd quarter valued at $4,396,000. Venturi Wealth Management LLC increased its holdings in shares of Boston Scientific by 1.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,035 shares of the medical equipment provider’s stock worth $882,000 after purchasing an additional 169 shares in the last quarter. Finally, Benjamin Edwards Inc. increased its holdings in Boston Scientific by 3.8% in the 3rd quarter. Benjamin Edwards Inc. now owns 18,426 shares of the medical equipment provider’s stock worth $1,799,000 after buying an additional 670 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $98.43 on Friday. The stock has a market cap of $145.92 billion, a P/E ratio of 52.64, a P/E/G ratio of 1.75 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock’s fifty day moving average is $97.64 and its 200 day moving average is $100.81. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the business posted $0.63 earnings per share. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BSX has been the topic of several research analyst reports. Cowen restated a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Royal Bank Of Canada increased their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Finally, Morgan Stanley increased their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $124.35.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.